| Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference |
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, and Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat at the H.C. |
globenewswire.com |
2025-05-13 12:00:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript |
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director of Investor Relations John Butler - Chief Executive Officer Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial and Chief Business Officer Conference Call Participants Roanna Ruiz - Leerink Partners Roger Song - Jefferies Allison Bratzel - Piper Sandler Les Siloski - Truist Securities Operator Good day and thank you for standing by. Welcome to Akebia's First Quarter 2025 Financial Results Call. |
seekingalpha.com |
2025-05-08 16:44:08 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates |
Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago. |
zacks.com |
2025-05-08 13:21:04 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights |
Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of $55.8 million Bolstered balance sheet and expanded institutional investor ownership through $50 million underwritten public offering of common stock; cash and cash equivalents of $113.4 million as of the end of the quarter Akebia to Host Conference Call at 8:00 a.m. ET on May 8, 2025 CAMBRIDGE, Mass. |
globenewswire.com |
2025-05-08 11:00:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 148,000 shares of Akebia's common stock on April 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-05-01 20:15:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? |
Akebia Therapeutics (AKBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-01 15:07:53 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights |
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, prior to the open of financial markets. |
globenewswire.com |
2025-05-01 12:00:00 |
Czytaj oryginał (ang.) |
| Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock |
Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. |
zacks.com |
2025-04-10 14:00:59 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa |
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) to approve XOANACYL® (Ferric Citrate as Coordination Complex) for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease (CKD). |
globenewswire.com |
2025-04-03 12:00:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 73,325 shares of Akebia's common stock on March 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-04-02 20:05:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025 |
CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25), which will take place in Boston, MA from April 10-13, 2025. |
globenewswire.com |
2025-03-25 10:00:00 |
Czytaj oryginał (ang.) |
| Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering |
AKBA's shares fell after announcing the pricing of its secondary issue of shares, which were at a discount to the previous closing price. |
zacks.com |
2025-03-21 16:05:29 |
Czytaj oryginał (ang.) |
| JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session |
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Thursday. |
benzinga.com |
2025-03-20 10:18:13 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics Announces Pricing of Public Offering of Common Stock |
CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of its underwritten public offering (the “Offering”) of 25,000,000 shares of its common stock at a public offering price of $2.00 per share. All shares are being offered by Akebia. The gross proceeds to Akebia from the Offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be $50.0 million. In addition, Akebia has granted the underwriters a 30-day option to purchase up to 3,750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on March 21, 2025, subject to the satisfaction of customary closing conditions. |
globenewswire.com |
2025-03-20 00:17:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics Announces Proposed Public Offering of Common Stock |
CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has commenced an underwritten public offering (the “Offering”). All shares are being offered by Akebia. In addition, Akebia expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the Offering at the public offering price, less underwriting discounts and commissions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. |
globenewswire.com |
2025-03-19 18:01:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript |
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q4 2024 Earnings Conference Call March 13, 2025 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, IR John Butler - CEO Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial & Business Officer Conference Call Participants Allison Bratzel - Piper Sandler Julian Harrison - BTIG Ed Arce - H.C. Wainwright Operator Good day, and welcome to Akebia's Fourth Quarter 2024 Financial Results Call. |
seekingalpha.com |
2025-03-13 12:21:25 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates |
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago. |
zacks.com |
2025-03-13 11:10:32 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update |
Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 million Cash resources and cash from operations expected to fund current operating plan for at least two years Akebia to Host Conference Call at 8:00 a.m. ET on March 13, 2025 CAMBRIDGE, Mass. |
globenewswire.com |
2025-03-13 09:00:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights |
CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 13, 2025, prior to the open of financial markets. |
globenewswire.com |
2025-03-06 10:00:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 13,525 shares of Akebia's common stock on February 28, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-03-04 18:05:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline |
Akebia Therapeutics is currently shifting focus from Auryxia to Vafseo due to Auryxia's declining revenues from patent expiration. Vafseo is now approved for dialysis patients and leverages AKBA's signature HIF pathway. So far, it has shown some early successes, which makes me optimistic. AKBA is also working on a Phase 3 trial for non‑dialysis CKD patients, which is scheduled for mid‑2025 to support a potential label expansion. |
seekingalpha.com |
2025-02-10 07:43:35 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted seven newly-hired employees options to purchase an aggregate of 130,763 shares of Akebia's common stock on January 31, 2025. The options were granted as an inducement material to teach employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-02-04 18:05:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics Announces Multiple Positive Business Updates |
New Commercial Supply Contracts for Vafseo® (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S. Vafseo tablets now shipping in the U.S. Plan to start Phase 3 trial in mid-2025 to potentially expand Vafseo label to include treatment of late-stage non-dialysis CKD patients Company to discuss business updates at 43rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass. |
prnewswire.com |
2025-01-13 10:00:00 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for January 3rd |
AKBA, KOF and GES have been added to the Zacks Rank #24 (Strong Sell) List on January 3, 2024. |
zacks.com |
2025-01-03 08:05:31 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass. , Jan. 2, 2025 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 3,000 shares of Akebia's common stock on December 31, 2024. |
prnewswire.com |
2025-01-02 18:05:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the 43rd Annual J.P. |
prnewswire.com |
2024-12-18 10:00:00 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for December 5th |
AKBA, KOF and XRAY have been added to the Zacks Rank #5 (Strong Sell) List on December 5, 2024. |
zacks.com |
2024-12-05 08:51:08 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass. , Dec. 3, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted nine newly-hired employees options to purchase an aggregate of 121,000 shares of Akebia's common stock on November 29, 2024. |
prnewswire.com |
2024-12-03 18:05:00 |
Czytaj oryginał (ang.) |
| U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis |
Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of care CAMBRIDGE, Mass. , Dec. 3, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that in late November U.S. Renal Care (USRC) enrolled the first patient in its Vafseo® (vadadustat) Outcomes In-Center Experience (VOICE) collaborative trial. |
prnewswire.com |
2024-12-03 09:00:00 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for November 27th |
AKBA, ABG and CLH have been added to the Zacks Rank #5 (Strong Sell) List on November 27, 2024. |
zacks.com |
2024-11-27 07:46:20 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference |
CAMBRIDGE, Mass. , Nov. 25, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a Fireside Discussion at the 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3 rd at 10:30 AM EST. |
prnewswire.com |
2024-11-25 10:00:00 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for November 22nd |
ATI, AKBA and ALTG have been added to the Zacks Rank #5 (Strong Sell) List on November 22, 2024. |
zacks.com |
2024-11-22 06:56:19 |
Czytaj oryginał (ang.) |
| Q3 2024 Earnings: Hold Akebia Therapeutics |
Akebia Therapeutics, Inc.'s stock has surged nearly 35% after positive updates on its Vafseo (vadadustat) and promising third-quarter results, despite macroeconomic challenges. The company is expanding its market through partnerships and trials, addressing unmet needs in anemia treatment for CKD patients, and exploring label expansion. Risks include potential competition post-2025 due to patent expiration for Auryxia, but current limited competition and strong brand recognition mitigate this. |
seekingalpha.com |
2024-11-20 17:31:29 |
Czytaj oryginał (ang.) |
| Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease |
Akebia continues to publish important results of FO2CUS trial to further physicians' understanding of Vafseo® (vadadustat) CAMBRIDGE, Mass. , Nov. 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the American Journal of Kidney Disease has published the results of FO2CUS, an open-label study evaluating the efficacy and safety of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, in hemodialysis patients who were converted from a long-acting erythropoiesis-stimulating agent (ESA) to three times weekly oral vadadustat dosing for the maintenance treatment of anemia. |
prnewswire.com |
2024-11-14 10:00:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics to Present at the Jefferies London Healthcare Conference |
CAMBRIDGE, Mass. , Nov. 12, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Thursday, November 21 at 1:00 PM GMT. |
prnewswire.com |
2024-11-12 10:00:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript |
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Investor Relations John Butler - Chief Executive Officer Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial and Business Officer Conference Call Participants Allison Bratzel - Piper Sandler Ed Arce - H.C. Wainwright Julian Harrison - BTIG Operator Good day and thank you for standing by. |
seekingalpha.com |
2024-11-07 15:59:54 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates |
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago. |
zacks.com |
2024-11-07 11:15:23 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights |
Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025 Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for Vafseo Vafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System code Akebia to Host Conference Call at 8:00 a.m. ET on November 7 CAMBRIDGE, Mass. |
prnewswire.com |
2024-11-07 09:00:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass. , Nov. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 20,000 shares of Akebia's common stock on October 31, 2024. |
prnewswire.com |
2024-11-01 18:05:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights |
Akebia to Host Conference Call on November 7, 2024, at 8:00 a.m. EST CAMBRIDGE, Mass. |
prnewswire.com |
2024-11-01 10:00:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis |
Contract in place with a comprehensive kidney care provider serving more than 200,000 patients at its thousands of U.S. dialysis centers CAMBRIDGE, Mass. , Oct. 22, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has signed a multi-year commercial contract with one of the nation's leading providers of kidney care services, expanding access to Vafseo® (vadadustat) for patients on dialysis. |
prnewswire.com |
2024-10-22 12:00:00 |
Czytaj oryginał (ang.) |
| Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 |
Vadadustat clinical data on display for nephrologist and healthcare providers in advance of U.S. market availability expected in January 2025 CAMBRIDGE, Mass. , Oct. 15, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week 2024 (ASN Kidney Week), which will take place in San Diego, CA from October 24-27. |
prnewswire.com |
2024-10-15 12:00:00 |
Czytaj oryginał (ang.) |
| CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 |
Designed to help dialysis organizations incorporate new treatments into their practices, TDAPA provides two years of reimbursement in addition to the ESRD bundled rate A HCPCS code has also been assigned to Vafseo to facilitate reimbursement at dialysis organizations CAMBRIDGE, Mass. , Oct. 10, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Center for Medicare & Medicaid Services (CMS) has determined that Vafseo® (vadadustat) meets the criteria for the Transitional Drug Add-On Payment Adjustment (TDAPA) in the anemia management end-stage renal disease (ESRD) prospective payment system functional category, beginning on January 1, 2025. |
prnewswire.com |
2024-10-10 12:00:00 |
Czytaj oryginał (ang.) |